Hyperinsulinism Clinical Trials

8 recruiting

Hyperinsulinism Trials at a Glance

13 actively recruiting trials for hyperinsulinism are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Houston, Bethesda, and Boston. Lead sponsors running hyperinsulinism studies include Attikon Hospital, Colorado State University, and Ali Chappell.

Browse hyperinsulinism trials by phase

Treatments under study

About Hyperinsulinism Clinical Trials

Looking for clinical trials for Hyperinsulinism? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hyperinsulinism trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hyperinsulinism clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

Congenital Hyperinsulinism
Miguel Pampaloni50 enrolled1 locationNCT04205604
Recruiting

Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

ObesityInsulin ResistanceHyperinsulinism+2 more
Ali Chappell150 enrolled1 locationNCT05950282
Recruiting
Not Applicable

Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes

Insulin ResistanceHyperinsulinismDepression+5 more
Colorado State University300 enrolled2 locationsNCT05543083
Recruiting
Phase 3

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Tumor Hyperinsulinism (Tumor HI)
Rezolute16 enrolled13 locationsNCT06881992
Recruiting
Phase 3

18F-DOPA II - PET Imaging Optimization

Neuroendocrine TumorsBrain TumorNeuroblastoma+3 more
University of Alberta800 enrolled1 locationNCT04706910
Recruiting

Understanding Beta Cell Disorders Through the Study of Rare Genotypes (ENDURE)

Diabetes MellitusHyperinsulinismMonogenic Diabetes
University of Exeter50 enrolled1 locationNCT06478121
Recruiting
Phase 2

Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism

Hyperinsulinism
Washington University School of Medicine100 enrolled1 locationNCT05088798
Recruiting

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

HyperinsulinismMetabolic SyndromePCOS+1 more
Attikon Hospital120 enrolled1 locationNCT06889454
Recruiting
Phase 1

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy

Breast CancerHER2-negative Breast CancerHyperinsulinism
Yale University20 enrolled1 locationNCT05989347
Recruiting
Phase 2

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

Congenital Hyperinsulinism
Hanmi Pharmaceutical Company Limited16 enrolled7 locationsNCT04732416
Recruiting
Not Applicable

Acute Microbial Switch

HyperinsulinismInsulin SensitivityGlucose Metabolism Disorders (Including Diabetes Mellitus)
Maastricht University Medical Center28 enrolled2 locationsNCT05764200
Recruiting
Phase 1

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Congenital HyperinsulinismInsulinoma
Cook Children's Health Care System250 enrolled1 locationNCT02021604
Recruiting
Early Phase 1

A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

Metastatic Breast CancerHyperinsulinismHyperglycemia Drug Induced
Rambam Health Care Campus30 enrolled1 locationNCT05753657